<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23233">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01713413</url>
  </required_header>
  <id_info>
    <org_study_id>OXYM2012</org_study_id>
    <nct_id>NCT01713413</nct_id>
  </id_info>
  <brief_title>Effects of an Oxymizer on Endurance Time in Patients With Chronic Lung Diseases</brief_title>
  <official_title>Effects of an Oxymizer Versus Conventional Nasal Cannula on Endurance Time in Patients With Chronic Obstructive Pulmonary Disease IV (COPD) or Interstitial Lung Disease (ILD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum Berchtesgadener Land der Schön-Kliniken</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum Berchtesgadener Land der Schön-Kliniken</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Oxymizer pendant® is a special oxygen cannula that can be used to supply high flow long
      term oxygen therapy. It is compatible with a wide variety of oxygen sources. In a reservoir,
      the Oxymizer® stores pure oxygen so that the concentration of inhaled oxygen is increased.

      The aim of this study is to investigate the potential benefit of the Oxymizer® with regard
      to the blood oxygenation during exercise testing. Given that the &quot;endurance time&quot; is very
      sensitive for little changes in exercise capacity, this test will be used to show the
      difference between the Oxymizer® and a conventional nasal cannula regarding exercise
      duration at 70% of peak Watt and oxygenation.

      The tests will be accompanied by blood gas analysis, partial pressure of carbon dioxide and
      heart rate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Difference between Endurance time with Oxymizer and conventional nasal cannula</measure>
    <time_frame>From starting until stopping cycling, up to 60 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in oxygen saturation with Oxymizer and with conventional nasal cannula</measure>
    <time_frame>stopping cycling, up to 60 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in PaCO2 with Oxymizer and with conventional nasal cannula</measure>
    <time_frame>Stopping cycling, up to 60 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>measured by Sentec device</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>COPD</condition>
  <condition>Interstitial Lung Disease</condition>
  <arm_group>
    <arm_group_label>Oxymizer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Using first the Oxymizer and 24 h later the conventional nasal cannula.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nasal cannula</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Using first the conventional nasal cannula and 24 h later the Oxymizer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oxymizer</intervention_name>
    <description>Using first the Oxymizer and 24 h later the conventional nasal cannula.</description>
    <arm_group_label>Oxymizer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>conventional nasal cannula</intervention_name>
    <description>Using first the conventional nasal cannula and 24h later the Oxymizer</description>
    <arm_group_label>nasal cannula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD IV

          -  interstitial lung disease

          -  long-term oxygen therapy with oxygen flow rate &gt;= 2 L/min

        Exclusion Criteria:

          -  acute cardial decompensation

          -  usual kontraindication for exposure test (higher-grad Hypertension (arterial and
             pulmonal), cardiac valve vitien, instabile angina pectoris, cardiac arrhythmia)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Klinikum Berchtesgadener Land</name>
      <address>
        <city>Berchtesgaden</city>
        <state>Bavaria</state>
        <zip>83714</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 14, 2014</lastchanged_date>
  <firstreceived_date>February 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum Berchtesgadener Land der Schön-Kliniken</investigator_affiliation>
    <investigator_full_name>Klaus Kenn</investigator_full_name>
    <investigator_title>Head physician (department of pneumology)</investigator_title>
  </responsible_party>
  <keyword>Oxymizer</keyword>
  <keyword>endurance time</keyword>
  <keyword>exercise test</keyword>
  <keyword>nasal cannula</keyword>
  <keyword>COPD</keyword>
  <keyword>ILD</keyword>
  <keyword>oxygenation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
